Literature DB >> 25937010

Non-electrophilic modulators of the canonical Keap1/Nrf2 pathway.

B G Richardson1, A D Jain1, T E Speltz1, T W Moore2.   

Abstract

Nrf2 is the major transcription factor that regulates many of the cytoprotective enzymes involved in the adaptive stress response. Modulation of Nrf2 could be therapeutically useful in a number of disease states. Activation can occur through either an electrophilic or non-electrophilic mechanism. To date, most of the research has focused on electrophilic Nrf2 activators, but there is increasing interest in non-electrophilic modulators of Nrf2. This Digest examines the current selection of small molecules that modulate Nrf2 through non-electrophilic mechanisms, and it highlights new opportunities for this important therapeutic target.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adaptive stress response; Cul3; Keap1; Nrf2; Nrf2 activator; Nrf2 repressor; Nrf2/Keap1 interaction; Protein–protein interaction

Mesh:

Substances:

Year:  2015        PMID: 25937010      PMCID: PMC4643947          DOI: 10.1016/j.bmcl.2015.04.019

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  66 in total

1.  Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.

Authors:  Shih-Ching Lo; Xuchu Li; Michael T Henzl; Lesa J Beamer; Mark Hannink
Journal:  EMBO J       Date:  2006-08-03       Impact factor: 11.598

2.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

Authors:  Jonathan B Baell; Georgina A Holloway
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription.

Authors:  Y Katoh; K Itoh; E Yoshida; M Miyagishi; A Fukamizu; M Yamamoto
Journal:  Genes Cells       Date:  2001-10       Impact factor: 1.891

4.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

5.  BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase.

Authors:  Manabu Furukawa; Yue Xiong
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

6.  RXRα inhibits the NRF2-ARE signaling pathway through a direct interaction with the Neh7 domain of NRF2.

Authors:  Hongyan Wang; Kaihua Liu; Miao Geng; Peng Gao; Xiaoyuan Wu; Yan Hai; Yangxia Li; Yulong Li; Lin Luo; John D Hayes; Xiu Jun Wang; Xiuwen Tang
Journal:  Cancer Res       Date:  2013-04-23       Impact factor: 12.701

7.  Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.

Authors:  Xiao-Jun Wang; Zheng Sun; Nicole F Villeneuve; Shirley Zhang; Fei Zhao; Yanjie Li; Weimin Chen; Xiaofang Yi; Wenxin Zheng; Georg T Wondrak; Pak Kin Wong; Donna D Zhang
Journal:  Carcinogenesis       Date:  2008-04-15       Impact factor: 4.944

8.  Small molecules inhibit the interaction of Nrf2 and the Keap1 Kelch domain through a non-covalent mechanism.

Authors:  Douglas Marcotte; Weike Zeng; Jean-Christophe Hus; Andres McKenzie; Cathy Hession; Ping Jin; Chris Bergeron; Alexey Lugovskoy; Istvan Enyedy; Hernan Cuervo; Deping Wang; Cédric Atmanene; Dominique Roecklin; Malgorzata Vecchi; Valérie Vivat; Joachim Kraemer; Dirk Winkler; Victor Hong; Jianhua Chao; Matvey Lukashev; Laura Silvian
Journal:  Bioorg Med Chem       Date:  2013-04-19       Impact factor: 3.641

9.  Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.

Authors:  Eva Havrdova; Michael Hutchinson; Nuwan C Kurukulasuriya; Kartik Raghupathi; Marianne T Sweetser; Katherine T Dawson; Ralf Gold
Journal:  Expert Opin Pharmacother       Date:  2013-08-24       Impact factor: 3.889

10.  Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex.

Authors:  Liam Baird; David Llères; Sam Swift; Albena T Dinkova-Kostova
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-28       Impact factor: 11.205

View more
  18 in total

1.  Isoquinoline Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-like 2 (KEAP1-NRF2) Inhibitors with High Metabolic Stability.

Authors:  Phillip R Lazzara; Brian P David; Aparna Ankireddy; Benjamin G Richardson; Katherine Dye; Kiira M Ratia; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2019-11-14       Impact factor: 7.446

2.  Replacement of a Naphthalene Scaffold in Kelch-like ECH-Associated Protein 1 (KEAP1)/Nuclear Factor (Erythroid-derived 2)-like 2 (NRF2) Inhibitors.

Authors:  Benjamin G Richardson; Atul D Jain; Haranatha R Potteti; Phillip R Lazzara; Brian P David; Chandra R Tamatam; Ewelina Choma; Kornelia Skowron; Katherine Dye; Zamia Siddiqui; Yue-Ting Wang; Aleksej Krunic; Sekhar P Reddy; Terry W Moore
Journal:  J Med Chem       Date:  2018-08-31       Impact factor: 7.446

3.  Polar Recognition Group Study of Keap1-Nrf2 Protein-Protein Interaction Inhibitors.

Authors:  Meng-Chen Lu; Shi-Jie Tan; Jian-Ai Ji; Zhi-Yun Chen; Zhen-Wei Yuan; Qi-Dong You; Zheng-Yu Jiang
Journal:  ACS Med Chem Lett       Date:  2016-07-05       Impact factor: 4.345

4.  Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.

Authors:  Atul D Jain; Haranatha Potteti; Benjamin G Richardson; Laura Kingsley; Julia P Luciano; Aya F Ryuzoji; Hyun Lee; Aleksej Krunic; Andrew D Mesecar; Sekhar P Reddy; Terry W Moore
Journal:  Eur J Med Chem       Date:  2015-09-04       Impact factor: 6.514

5.  Perspectives on the Clinical Development of NRF2-Targeting Drugs.

Authors:  Diego Lastra; Raquel Fernández-Ginés; Gina Manda; Antonio Cuadrado
Journal:  Handb Exp Pharmacol       Date:  2021

6.  Identification of Non-Electrophilic Nrf2 Activators from Approved Drugs.

Authors:  Qing-Ye Zhang; Xin-Yi Chu; Ling-Han Jiang; Meng-Yuan Liu; Zhi-Ling Mei; Hong-Yu Zhang
Journal:  Molecules       Date:  2017-05-26       Impact factor: 4.411

Review 7.  Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages.

Authors:  Larissa Staurengo-Ferrari; Stephanie Badaro-Garcia; Miriam S N Hohmann; Marília F Manchope; Tiago H Zaninelli; Rubia Casagrande; Waldiceu A Verri
Journal:  Front Pharmacol       Date:  2019-01-11       Impact factor: 5.810

8.  Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.

Authors:  Dhulfiqar Ali Abed; Sumi Lee; Xia Wen; Ahmed R Ali; Vaibhav Mangipudy; Lauren M Aleksunes; Longqin Hu
Journal:  Bioorg Med Chem       Date:  2021-07-01       Impact factor: 3.461

9.  Exploring the inhibitory potentials of Momordica charantia bioactive compounds against Keap1-Kelch protein using computational approaches.

Authors:  Temitope Isaac Adelusi; Misbaudeen Abdul-Hammed; Mukhtar Oluwaseun Idris; Oyedele Qudus Kehinde; Ibrahim Damilare Boyenle; Ukachi Chiamaka Divine; Ibrahim Olaide Adedotun; Ajayi Ayodeji Folorunsho; Oladipo Elijah Kolawole
Journal:  In Silico Pharmacol       Date:  2021-06-25

Review 10.  p62-Keap1-NRF2-ARE Pathway: A Contentious Player for Selective Targeting of Autophagy, Oxidative Stress and Mitochondrial Dysfunction in Prion Diseases.

Authors:  Syed Zahid Ali Shah; Deming Zhao; Tariq Hussain; Naveed Sabir; Mazhar Hussain Mangi; Lifeng Yang
Journal:  Front Mol Neurosci       Date:  2018-10-04       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.